359 related articles for article (PubMed ID: 29805708)
1. Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan.
Lin SY; Yang CY; Liao BC; Ho CC; Liao WY; Chen KY; Tsai TH; Hsu CL; Hsu WH; Su KY; Chang YL; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
J Cancer; 2018; 9(10):1813-1820. PubMed ID: 29805708
[No Abstract] [Full Text] [Related]
2. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1.
Velcheti V; Hu X; Yang L; Pietanza MC; Burke T
Front Oncol; 2022; 12():834761. PubMed ID: 35402266
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice.
Ahn BC; Pyo KH; Xin CF; Jung D; Shim HS; Lee CY; Park SY; Yoon HI; Hong MH; Cho BC; Kim HR
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1613-1623. PubMed ID: 30911841
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.
Hui R; Garon EB; Goldman JW; Leighl NB; Hellmann MD; Patnaik A; Gandhi L; Eder JP; Ahn MJ; Horn L; Felip E; Carcereny E; Rangwala R; Lubiniecki GM; Zhang J; Emancipator K; Roach C; Rizvi NA
Ann Oncol; 2017 Apr; 28(4):874-881. PubMed ID: 28168303
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.
Imai H; Wasamoto S; Yamaguchi O; Suzuki K; Sugiyama T; Uchino J; Minemura H; Osaki T; Ishii H; Umeda Y; Mori K; Kotake M; Kagamu H; Morozumi N; Taniguchi H; Kasai T; Minato K; Kaira K
J Cancer Res Clin Oncol; 2020 Feb; 146(2):457-466. PubMed ID: 31853661
[TBL] [Abstract][Full Text] [Related]
7. Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population.
Ahmadzada T; Cooper WA; Holmes M; Mahar A; Westman H; Gill AJ; Nordman I; Yip PY; Pal A; Zielinski R; Pavlakis N; Nagrial A; Daneshvar D; Brungs D; Karikios D; Aleksova V; Burn J; Asher R; Grau GE; Hosseini-Beheshti E; Reid G; Clarke S; Kao S
JTO Clin Res Rep; 2020 Nov; 1(4):100075. PubMed ID: 34589956
[TBL] [Abstract][Full Text] [Related]
8. Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease.
Shibaki R; Murakami S; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Kusumoto M; Yamamoto N; Ohe Y
Med Oncol; 2019 Apr; 36(6):49. PubMed ID: 31030326
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis.
Almutairi AR; Alkhatib N; Martin J; Babiker HM; Garland LL; McBride A; Abraham I
Crit Rev Oncol Hematol; 2019 Oct; 142():16-25. PubMed ID: 31326706
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study.
Shiotsu S; Yoshimura A; Yamada T; Morimoto K; Tsuchiya M; Yoshioka H; Hiranuma O; Chihara Y; Yamada T; Hasegawa I; Ohta T; Takeda T; Hiraoka N; Takayama K
Front Oncol; 2022; 12():904644. PubMed ID: 36158655
[TBL] [Abstract][Full Text] [Related]
11. Real-World Immunotherapy Use and Effectiveness in Advanced NSCLC With Programmed Death-Ligand 1 Greater Than or Equal to 50% and Greater Than or Equal to 90.
Jackson A; Chang N; Akurang D; Wheatley-Price P; Moore S
JTO Clin Res Rep; 2023 Dec; 4(12):100601. PubMed ID: 38162175
[TBL] [Abstract][Full Text] [Related]
12. A real-world retrospective, observational study of first-line pembrolizumab plus chemotherapy for metastatic non-squamous non-small cell lung cancer with PD-L1 tumor proportion score < 50% (PEMBROREAL).
Cafaro A; Foca F; Nanni O; Chiumente M; Coppola M; Baldo P; Orzetti S; Enrico F; Ladisa V; Lerose R; Nardulli P; Maiolino P; Gradellini F; Gasbarro AR; Carrucciu G; Provasi R; Cappelletto PC; Pasqualini A; Vecchia S; Veraldi M; De Francesco AE; Crinò L; Delmonte A; Masini C
Front Oncol; 2024; 14():1351995. PubMed ID: 38601759
[TBL] [Abstract][Full Text] [Related]
13. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 mRNA derived from tumor-educated platelets as a potential immunotherapy biomarker in non-small cell lung cancer.
Hu Z; Wang N; Zhang Y; Zhang D; Sun S; Yu H; Lin Y; Zhao X; Wang H; Wu X; Ichiki Y; Watanabe S; Gong Z; Chang J; Wang J
Transl Lung Cancer Res; 2024 Feb; 13(2):345-354. PubMed ID: 38496687
[TBL] [Abstract][Full Text] [Related]
15. A Multivariable Regression Model-based Nomogram for Estimating the Overall Survival of Patients Previously Treated With Nivolumab for Advanced Non-small-cell Lung Cancer.
Tamiya A; Tamiya M; Go H; Inoue T; Kunimasa K; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Nishino K; Kumagai T; Suzuki H; Hirashima T; Atagi S; Shintani A; Imamura F
Anticancer Res; 2020 Aug; 40(8):4229-4236. PubMed ID: 32727749
[TBL] [Abstract][Full Text] [Related]
16. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
[TBL] [Abstract][Full Text] [Related]
17. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
18. Impact of gender on response to immune checkpoint inhibitors in patients with non-small cell lung cancer undergoing second- or later-line treatment.
Choi MG; Choi CM; Lee DH; Kim SW; Yoon S; Ji W; Lee JC
Transl Lung Cancer Res; 2022 Sep; 11(9):1866-1876. PubMed ID: 36248340
[TBL] [Abstract][Full Text] [Related]
19. FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies.
Marur S; Singh H; Mishra-Kalyani P; Larkins E; Keegan P; Sridhara R; Blumenthal GM; Pazdur R
Semin Oncol; 2018 Aug; 45(4):220-225. PubMed ID: 30391014
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
